<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</title>
    <meta name="description" content="Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.; In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.; In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</h1>
<div class="muted">2025-09-15 14:27:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.</li><li>In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.</li><li>In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues.</li><li>In the first half of 2025, DefenCath delivered $78.8 million in net revenues, reflecting a solid start to its commercial journey.</li><li>CorMedix has also raised its guidance for DefenCath sales to the range of $200-$215 million in 2025 compared with the previous expectation of $180-$200 million in sales.</li><li>market exclusivity through 2033.</li><li>Management now expects 2025 pro forma revenues in the $325-$350 million range, with the deal projected to be accretive to earnings per share by 2026.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/cormedix-rallies-60-ytd-indication-142700729.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=CorMedix+Rallies+60%25+YTD%3A+Is+This+an+Indication+to+Buy+the+Stock%3F%0A%E2%80%A2+Shares+of+CorMedix+CRMD+have+soared+59.7%25+in+the+year-to-date+period.%0A%E2%80%A2+In+the+past+year%2C+CorMedix+shares+have+surged+83.3%25+against+the+industry%E2%80%99s+13.8%25+decline.%0A%E2%80%A2+In+2025%2C+CorMedix+anti%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fcormedix-rallies-60-ytd-is-this-an-indication-to-buy-the-stock%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>